

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1564	40	3%	270	-1293	138	-1426
ERLYTX	76	5	7%	33	-42	36	-40
GI	479	32	7%	216	-262	195	-284
GU	450	76	17%	513	63	502	52
GYN	57	0	0%	0	-57	0	-57
LEUK	150	10	7%	67	-82	53	-97
LUNG	524	143	27%	966	442	686	162
LYMPH	172	18	10%	121	-50	124	-48
MELAN	55	52	95%	351	296	417	362
MMYEL	147	38	26%	256	109	147	0
MULT	0	0		0	0	25	25
OTHER	0	7		47	47	44	44
PREV	0	0		0	0	4	4
SXQOL	0	2		13	13	5	5
Total	3674	423		2853	-816	2376	-1298

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		13	13	2	2
BREAST	43	1	2%	6	-36	6	-37
CCD	0	157		1061	1061	1012	1012
ERLYTX	0	3		20	20	6	6
GU	0	0		0	0	6	6
LEUK	69	0	0%	0	-69	0	-69
LUNG	43	60	140%	405	362	416	373
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	2		13	13	4	4
PEOLC	0	0		0	0	0	0
PREV	0	84		567	567	580	580
SURV	0	2		13	13	27	27
SXQOL	888	264	30%	1784	896	1429	541
Total	1188	575		3882	2695	3488	2300

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		13	13	2	2
BREAST	1607	41	3%	277	-1329	144	-1463
CCD	0	157		1061	1061	1012	1012
ERLYTX	76	8	11%	54	-21	42	-34
GI	479	32	7%	216	-262	195	-284
GU	450	76	17%	513	63	508	58
GYN	57	0	0%	0	-57	0	-57
LEUK	219	10	5%	67	-151	53	-166
LUNG	567	203	36%	1372	805	1102	535
LYMPH	225	18	8%	121	-103	124	-101
MELAN	55	52	95%	351	296	417	362
MMYEL	239	38	16%	256	17	147	-92
MULT	0	0		0	0	25	25
OTHER	0	9		60	60	48	48
PEOLC	0	0		0	0	0	0
PREV	0	84		567	567	584	584
SURV	0	2		13	13	27	27
SXQOL	888	266	30%	1797	909	1434	546
Total	4862	998		6738	1881	5864	1002

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1017	19	2%	128	-888	99	-918
ERLYTX	76	5	7%	33	-42	25	-51
GI	421	29	7%	196	-224	162	-259
GU	375	62	17%	419	44	392	17
GYN	57	0	0%	0	-57	0	-57
LEUK	122	6	5%	40	-81	33	-89
LUNG	441	92	21%	621	180	475	34
LYMPH	129	15	12%	101	-27	101	-28
MELAN	55	31	56%	209	154	254	199
MMYEL	85	27	32%	182	97	99	14
MULT	0	0		0	0	17	17
OTHER	0	5		33	33	42	42
PREV	0	0		0	0	4	4
SXQOL	0	2		13	13	5	5
Total	2778	293		1975	-798	1708	-1070

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		13	13	2	2
BREAST	16	1	6%	6	-9	6	-10
CCD	0	139		939	939	900	900
ERLYTX	0	3		20	20	6	6
GU	0	0		0	0	6	6
LEUK	69	0	0%	0	-69	0	-69
LUNG	30	42	140%	283	253	233	203
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	2		13	13	4	4
PEOLC	0	0		0	0	0	0
PREV	0	68		459	459	398	398
SURV	0	2		13	13	20	20
SXQOL	750	161	21%	1088	338	929	179
Total	1010	420		2834	1825	2504	1494

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	2		13	13	2	2
BREAST	1033	20	2%	135	-897	105	-928
CCD	0	139		939	939	900	900
ERLYTX	76	8	11%	54	-21	31	-45
GI	421	29	7%	196	-224	162	-259
GU	375	62	17%	419	44	398	23
GYN	57	0	0%	0	-57	0	-57
LEUK	191	6	3%	40	-150	33	-158
LUNG	471	134	28%	905	434	708	237
LYMPH	182	15	8%	101	-80	101	-81
MELAN	55	31	56%	209	154	254	199
MMYEL	177	27	15%	182	5	99	-78
MULT	0	0		0	0	17	17
OTHER	0	7		47	47	46	46
PEOLC	0	0		0	0	0	0
PREV	0	68		459	459	402	402
SURV	0	2		13	13	20	20
SXQOL	750	163	22%	1101	351	934	184
Total	3788	713		4813	1030	4212	424

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
15% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2024 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2024 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	40	62%	270	205	122	57
CCD	0	157		1061	1061	1012	1012
ERLYTX	0	0		0	0	1	1
GI	81	2	2%	13	-67	31	-50
GU	215	66	31%	446	231	423	208
LEUK	0	7		47	47	37	37
LUNG	53	44	83%	297	244	234	181
LYMPH	7	10	143%	67	60	60	53
MELAN	0	0		0	0	0	0
MMYEL	0	10		67	67	38	38
OTHER	0	2		13	13	16	16
PEOLC	0	0		0	0	0	0
PREV	0	59		398	398	422	422
SURV	0	2		13	13	27	27
<u>SXQOL</u>	<u>880</u>	<u>266</u>	<u>30%</u>	<u>1797</u>	<u>917</u>	<u>1434</u>	<u>554</u>
Total	1301	665		4489	3189	3857	2556

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		CCTGHN11	CCTG			1			
		EAY191A3	ALLIANCE			1			
		NRGBN005	NRG			0			
BREAST	II	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG	13APR2017:00:00:00		7			Dec-2022 Temp Close
		S1706 Breast, Inflammatory, RT +/- Olaparib	SWOG	12SEP2018:00:00:00	65	145	300	1.8	Feb-2031
		S2007 Breast, Brain Mets, Sacituzumab Govitecan	SWOG	15DEC2020:00:00:00	38	23	44	0.3	Apr-2029
	II-III	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG	24DEC2014:00:00:00		1			May-2022 Temp Close
	III	A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib	ALLIANCE	06JAN2021:00:00:00		41		1.8	
		A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab	ALLIANCE	03MAY2023:00:00:00		5		0.8	
		MA39 BREAST, Node-Pos, Reg RT vs No Reg RT	CCTG	30MAY2018:00:00:00		23		0.7	
		NRGBR007 Breast, Stg I, De-Escalation of Breast RT	NRG	07JUN2021:00:00:00		8		0.3	
		NRGBR009 Breast, EarlyStg, Adjuvant Chemo	NRG	31AUG2023:00:00:00		1		0.2	
		S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva	SWOG	30OCT2023:00:00:00	3	2	960	0.5	> 15 Yrs
		S2212 Breast, TNBC, Neoadj Chemo + Pembro	SWOG	21JUL2023:00:00:00	7	57	2400	9.5	> 15 Yrs
CCD	III	A191901 Brst, Text/Motivational Intervention ET Adher	ALLIANCE	10DEC2020:00:00:00		39		0.0	
		S1703 Met Breast, STM-monitoring v Usual Care	SWOG	16JUL2018:00:00:00	67	320	739	4.0	Oct-2032
		S1912CD CREDIT, Fin Counseling to reduce Fin Hardship	SWOG	26JUL2021:00:00:00	30	200	326	16.5	Sep-2024
		S2108CD Genomic Tumor Board vs Usual Practice	SWOG	22AUG2022:00:00:00	18	882	1182	58.3	Jul-2024
	OTHER	A231602C Blood Cancer, Assess Financial Difficulty	ALLIANCE	15MAR2019:00:00:00		4			Feb-2021 Temp Close
		ACCL16N1 Guideline Consistent Treatment AYA ALL	COG	18DEC2017:00:00:00		54			Aug-2022 Temp Close
		NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		236		3.2	
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	28AUG2015:00:00:00		8		0.0	
		EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib	SWOG	06MAR2023:00:00:00	11	1	33	0.2	> 15 Yrs
		EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib	ECOG-ACRIN	07JUN2023:00:00:00		3		0.3	
	II-III	S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo	SWOG	02DEC2021:00:00:00	26	37	189	2.3	Jul-2029
	III	AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult	COG	08MAY2017:00:00:00		2		0.0	
	OTHER	EAY191 ComboMATCH	ECOG-ACRIN	06MAR2023:00:00:00		6		0.8	
GI	II	A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM	ALLIANCE	16MAR2022:00:00:00		2		0.2	
		A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo	ALLIANCE	09NOV2022:00:00:00		43		5.7	
		EA2182 Anal, Erly, DECREASE	ECOG-ACRIN	12NOV2019:00:00:00		13		0.5	
		EA2192 Panc, APOLLO	ECOG-ACRIN	29APR2021:00:00:00		2		0.2	
		S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect	SWOG	16DEC2019:00:00:00	50	32	94	0.3	> 15 Yrs
		S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo	SWOG	04DEC2020:00:00:00	38	47	88	1.5	May-2026
		S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs	SWOG	14OCT2021:11:13:50	28	34	154	1.5	Sep-2030
		S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo	SWOG	06JUN2022:10:01:28	20	53	84	3.2	Nov-2024
	II-III	EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab	ECOG-ACRIN	17JAN2019:00:00:00		6		0.0	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		EA2197 Gal, Rando Perioperative TX	ECOG-ACRIN	22DEC2020:00:00:00		5		0.2	
		NRGGI008 Colon, Stg III, Adj Chemo	NRG	10MAR2022:00:00:00		14		1.0	
	III	A021806 Pancreas, Perioperative vs Adjuvant Chemo	ALLIANCE	01JUL2020:00:00:00		28		1.0	
		A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/- Nivo	ALLIANCE	11JAN2023:00:00:00		8		0.8	
		EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo	ECOG-ACRIN	15OCT2020:00:00:00		25		1.0	
		NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG	07NOV2017:00:00:00	75	15		0.0	
GU	II	A031701 Bladder, ddGC for MIBC with DDR Tumor Alt	ALLIANCE	01AUG2018:00:00:00		19		0.3	
		A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC)	ALLIANCE	12APR2019:00:00:00		26		0.0	
		A031801 GU, mRCC, Cabozantinib +/- Radium-223	ALLIANCE	13DEC2019:00:00:00		14		0.7	
		A031803 Blad, NMIBC, Gemcitabine + MK-3475	ALLIANCE	06JAN2020:00:00:00		40		0.2	
		A032101 Pros, MHSPC ADT Interruption	ALLIANCE	15JUL2022:00:00:00		12		1.7	
		EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi	ECOG-ACRIN	09JUL2018:00:00:00		87		0.0	
		NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx	NRG	08DEC2021:00:00:00		8		1.2	
		NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy	NRG	30JUN2022:00:00:00		2		0.3	
		S2200 pRCC, Adv, Cabo +/- Atezo	SWOG	19SEP2022:00:00:00	17	11	200	1.0	> 15 Yrs
		S2210 Pros, High Risk, BRCA, Neoadj Carbo	SWOG	14AUG2023:00:00:00	6	0	44	0.0	> 15 Yrs
	II-III	EA8192 Blad, High Grade UTUC, Durv + Chemo	ECOG-ACRIN	06MAY2021:00:00:00		2		0.0	
	III	A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo	ALLIANCE	09MAY2019:00:00:00		119		1.3	
		A032001 Blad, Met, Cabo +/- Avelumab after Chemo	ALLIANCE	10MAR2022:00:00:00		15		0.5	
		EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT	ECOG-ACRIN	08SEP2017:00:00:00		12		0.2	
		EA8191 Pros, Local vs Systemic Thrpy	ECOG-ACRIN	08OCT2020:00:00:00		28		1.2	
		EA8212 Blad, NMIBC, BRIDGE	ECOG-ACRIN	01DEC2022:00:00:00		81		7.5	
		NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide	NRG	05MAR2020:00:00:00		12		0.7	
		NRGGU009 Pros, PREDICT-RT	NRG	15DEC2020:00:00:00		40		3.3	
		NRGGU010 Pros, Parallel De-Intens & Intens Trials	NRG	03NOV2021:00:00:00		29		1.7	
		S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	SWOG	17SEP2018:00:00:00	65	767	1273	10.0	Apr-2028
		S1806 Blad, MIBC, ChemoRT +/- Atezolizumab	SWOG	19APR2019:00:00:00	58	478	475	8.8	Feb-2024
		S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only	SWOG	16NOV2020:00:00:00	39	87	332	2.8	Apr-2031
		S1937 Blad, Mets, Eribulin +/- Gem vs SOC	SWOG	16FEB2021:00:00:00	36	23	465	0.0	> 15 Yrs
LEUK	I-II	EA9152 ALL, T/B-Cell, Venetoclax + Vincristine	ECOG-ACRIN	26APR2018:00:00:00		3		0.2	
		S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424	SWOG	17AUG2020:00:00:00	42	14	64	0.2	> 15 Yrs
	II	A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat	ALLIANCE	16NOV2018:00:00:00		5		0.2	
		A042001 B-Cell ALL, Inotuzunab+chemo v Standard chemo	ALLIANCE	27FEB2023:00:00:00		2		0.3	
		EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs	ECOG-ACRIN	03OCT2018:00:00:00		4		0.3	
		EA9213 T-ALL, dara-hyal for chemo refractory MRD	ECOG-ACRIN	16JUN2022:00:00:00		3		0.3	
	II-III	A041701 AML, Age 60+, Conv Chemo +/- Uproleselan	ALLIANCE	16JAN2019:00:00:00		38		0.0	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	III	A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	ALLIANCE	01JUN2017:00:00:00		44		0.0	
		EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab	ECOG-ACRIN	14OCT2020:00:00:00		31		0.3	
		S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O	SWOG	14DEC2020:00:00:00	38	92	247	2.8	Aug-2028
LUNG	II	EA5162 NSCLS,StgIV/IIB,EGFR exon20 insertion,AZD9291	ECOG-ACRIN	05APR2018:00:00:00		1		0.2	
		S1900E KRAS G12C: Sotorasib (AMG 510)	SWOG	02APR2021:00:00:00	34	109	116	2.0	May-2024
		S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu	SWOG	03APR2023:00:00:00	10	9	66	1.0	Oct-2028
		S1900K MET Exon 14: Tepotinib +/- Ramucirumab	SWOG	18DEC2023:00:00:00	2	0	56		
		S1933 NSCLC, Stg II-III, RT + Atezo	SWOG	15JUN2020:10:15:53	44	35	47	0.8	Apr-2025
	II-III	A082002 Lung, Adv, Systemic Tx +/- SBRT	ALLIANCE	21DEC2021:00:00:00		4		0.2	
	III	A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO	ALLIANCE	03JUN2020:00:00:00		70		1.2	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACRIN	18AUG2014:00:00:00		22		0.8	
		EA5163 NSCLC, Immunotherapy +/- 2nd line therapy	ECOG-ACRIN	28FEB2019:00:00:00		83		1.7	
		EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291	ECOG-ACRIN	22OCT2020:00:00:00		13		0.5	
		NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo	NRG	10MAY2023:00:00:00		1		0.2	
		S1827 SCLC, MRI Surveillance +/- PCI	SWOG	10JAN2020:00:00:00	49	202	668	5.7	Dec-2030
		S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo	SWOG	25MAR2020:00:00:00	46	322	480	13.2	Jan-2025
		S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC	SWOG	06MAR2023:08:56:25	11	345	700	41.7	Oct-2024
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	18AUG2014:00:00:00		972		2.7	
		LUNGMAP NSCLC, Adv, Master	SWOG	28JAN2019:00:00:00	60	3303		25.8	
LYMPH	I-II	E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin	ECOG-ACRIN	24JAN2014:00:00:00		20		0.0	
	II	A051902 PTCL,CHO(E)PvCC-486-CHO(E)PvDuvelisib-CHO(E)P	ALLIANCE	30JUL2021:00:00:00		1		0.2	
		S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	SWOG	10AUG2017:00:00:00	78	77	95	0.7	Apr-2026
		S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation	SWOG	23FEB2023:11:55:36	12	32	396	3.7	May-2032
		S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa	SWOG	30JUN2023:11:49:39	7	5	227	0.8	> 15 Yrs
	II-III	A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax	ALLIANCE	07AUG2019:00:00:00		34			Dec-2023 Temp Close
		S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP	SWOG	19MAR2021:00:00:00	35	88	422	4.2	Oct-2030
	III	A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub	ALLIANCE	08SEP2023:00:00:00		2		0.4	
		AHOD2131 cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy	COG	28APR2023:00:00:00		13		2.0	
		ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo	COG	07JUN2021:00:00:00		18		1.3	
		EA4151 Lymph, AHCT +/-Ritux, MRD Neg	ECOG-ACRIN	29AUG2017:00:00:00		121		0.8	
MELAN	II	A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo	ALLIANCE	01JUN2022:00:00:00		1		0.0	
		EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy	ECOG-ACRIN	27AUG2020:00:00:00		8		0.0	
		EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001	ECOG-ACRIN	19MAR2021:00:00:00		3		0.5	
		S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo	SWOG	23SEP2020:00:00:00	41	31	35	0.5	Sep-2024
	II-III	EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	10SEP2015:00:00:00		59		0.7	
	III	EA6174 Merkel, Adjuvant Pembrolizumab vs Observation	ECOG-ACRIN	23JUL2018:00:00:00		53		0.0	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S2015 MELAN, Stg I-II, 1cm v 2cm excision margins	MASC	08APR2022:00:00:00		515		33.7	
MMYEL	111	S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT	SWOG	01DEC2023:00:00:00	2	0	338		
	II	EAA173 MYEL, SMM, Rd +/- Daratumumab	ECOG-ACRIN	30APR2019:00:00:00		26		0.3	
	III	EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE)	ECOG-ACRIN	27OCT2020:00:00:00		33		1.5	
		S1803 MM, Maintenance, Len vs Len/Dara	SWOG	27JUN2019:00:00:00	55	1077	1100	6.0	May-2024
		S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D	SWOG	30MAY2023:00:00:00	8	15	510	2.5	> 15 Yrs
MULT	II	S2101 Melan or HNSCC, Adv, Cabo + Nivo	SWOG	14OCT2022:10:48:23	16	27	220	0.0	> 15 Yrs
OTHER	II	A071701 BRAIN, Met, Geno-guided trial	ALLIANCE	15AUG2019:00:00:00		2		0.0	
		A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma	ALLIANCE	30OCT2020:00:00:00		0		0.0	
		A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab	ALLIANCE	24MAR2023:00:00:00		3		0.5	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		21		0.0	
		EA3191 HN, High Risk HNSCC, Adj +/- Pembro	ECOG-ACRIN	08JAN2021:00:00:00		7		0.2	
		NRGHN010 HER2+ SGC, T-DM1 vs TH	NRG	30SEP2022:00:00:00		2		0.0	
	II-III	A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice	ALLIANCE	09DEC2022:00:00:00		5		0.8	
		EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo	ECOG-ACRIN	20JUN2019:00:00:00		59		1.5	
		NRGHN005 HN, early stg P16-pos, randomize de-intensifi	NRG	10JUL2019:00:00:00		8		0.2	
		NRGHN006 HN, Erly Stg, Biopsy vs Dissection	NRG	08JUL2020:00:00:00		2		0.0	
		NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN	NRG	27OCT2021:00:00:00		13		1.0	
		R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		6		0.0	
	III	AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo	COG	30JUL2018:00:00:00		4			Jan-2021 Temp Close
		ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO	COG	13SEP2021:00:00:00		1		0.0	
		N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	ALLIANCE	22SEP2009:00:00:00		12		0.0	
		NRGBN003 Mening, Grd II, Observation vs Irradiation	NRG	14JUN2017:00:00:00		3		0.0	
		NRGBN011 Brain, Lomustine + Temo vs Temo	NRG	29NOV2021:00:00:00		4		0.2	
		NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg	NRG	31AUG2022:00:00:00		1		0.0	
		NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono	NRG	26AUG2019:00:00:00		1		0.2	
	OTHER	A151804 irAEs, National Biorepository to Adv Studies	ALLIANCE	31JAN2020:00:00:00		22		0.5	
PREV	II	EA2185 Panc, Impact of Panc Cyst Surveillance	ECOG-ACRIN	16JAN2020:00:00:00		19		0.8	
		EA8184 Pros, Dbl Blind GTC vs Placebo	ECOG-ACRIN	20MAY2021:00:00:00		4		0.2	
	III	EA1151 Prev, Tomosynthesis Mammographic Screening	ECOG-ACRIN	06JUL2017:00:00:00		2434		13.8	
		NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs	NRG	06OCT2021:00:00:00		2		0.3	
	OTHER	A212102 Blind Ref Set for Multicancer Early Detection	ALLIANCE	01AUG2022:00:00:00		81		5.2	
		NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO	NRG	23JUN2020:00:00:00		9		0.5	
		S1823 GCT, Obs. Cohort, miRNA371	SWOG	01JUN2020:13:00:37	44	899	956	16.8	May-2024
	PILOT	S1904 Breast, Decision making for chemoprevention	SWOG	01SEP2020:00:00:00	41	371	415	10.0	Jun-2024

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
SURV	III	A211901 Cancer survivors who smoke, txt cessation	ALLIANCE	01DEC2021:00:00:00		4		0.7	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00		310	817		Feb-2024 Temp Close
SXQOL	II-III	A221805 Colorectal, Duloxetine for Oxaliplatin CIPN	ALLIANCE	01MAY2020:00:00:00		8		0.0	
	III	A222004 Mult, Olanza vs Megestrol for Anorexia	ALLIANCE	15OCT2021:00:00:00		3		0.2	
		NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction	NRG	19SEP2022:00:00:00		7		0.3	
		S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed	SWOG	17JAN2023:00:00:00	13	218	540	25.2	Feb-2025
		S2205 ICE COMPRESS: Reduction of CIPN from Taxanes	SWOG	16MAR2023:00:00:00	11	90	777	12.0	Nov-2028
	OTHER	S2013 I-CHECKIT: ICI toxicity risk prediction study	SWOG	16AUG2021:00:00:00	30	1838	2062	86.5	Apr-2024
	PILOT	EAQ202 Improving AYA PROs in EA Trials	ECOG-ACRIN	28OCT2021:00:00:00		43		0.0	

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA	
						Cntrl Study	Temp Close
OTHER	CCD	Y	COG	ACCL16N1 Guideline Consistent Treatment AYA ALL	ACCL16N1CD	Y	Y
		Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
		Y	ALLIANCE	A231602C Blood Cancer, Assess Financial Difficulty	A231602CD	Y	Y
	ERLYTX	Y	ECOG-ACRIN	EAY191 ComboMATCH	EAY191	N	
	LUNG	Y	SWOG	LUNGMAP NSCLC, Adv, Master	LUNGMAP	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ALLIANCE	A151804 irAEs, National Biorepository to Adv Studies	A151804	N	
	PREV	Y	SWOG	S1823 GCT, Obs. Cohort, miRNA371	S1823	Y	
		Y	ALLIANCE	A212102 Blind Ref Set for Multicancer Early Detection	A212102	Y	
		Y	NRG	NRGCC008 Ovar, BRCA1, non-inferiority of BLS vs BSO	NRG-CC008	Y	
SXQOL	Y	SWOG	S2013 I-CHECKIT: ICI toxicity risk prediction study	S2013	Y		
I-II	LEUK	Y	SWOG	S1905 T-ALL/T-LBL, Rel/Ref, OBI-3424	S1905	N	
		Y	ECOG-ACRIN	EA9152 ALL, T/B-Cell, Venetoclax + Vincristine	EA9152	N	
LYMPH	Y	ECOG-ACRIN	E4412 HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin	E4412	N		
II	BREAST	Y	SWOG	S1706 Breast, Inflammatory, RT +/- Olaparib	S1706	Y	
		Y	SWOG	S2007 Breast, Brain Mets, Sacituzumab Govitecan	S2007	N	
	Y	NRG	NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv	NRG-BR005	N	Y	
	ERLYTX	Y	SWOG	EAY191-S3 ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib	EAY191-S3	N	
Y		ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N		
Y		ECOG-ACRIN	EAY191E4 ComboMATCH-Pr. Tax-Tx Tumors, Pac+Nilotinib	EAY191-E4	N		
GI			EA2192 Panc, APOLLO		N		
	Y	SWOG	S2001 Rando II, Mets Pancreas , BRCA1/2, Comb Chemo	S2001	N		
	Y	SWOG	S1922 Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect	S1922	N		
	Y	SWOG	S2107 Colorectal, BRAF mut, Enc + CET +/-Nivo	S2107	N		
	Y	SWOG	S2104 Panc,Resect High-risk,Postop Adj Chemo vs Obs	S2104	N		
	Y	ALLIANCE	A022104 Rectal, Loc Adv, Triplet vs Doublet Chemo	A022104	N		
	Y	ECOG-ACRIN	EA2182 Anal, Erly, DECREASE	EA2182	Y		
GU	Y	ALLIANCE	A022001 PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM	A022001	Y		
	Y	SWOG	S2200 pRCC, Adv, Cabo +/- Atezo	S2200	N		
	Y	SWOG	S2210 Pros, High Risk, BRCA, Neoadj Carbo	S2210	N		
	Y	ECOG-ACRIN	EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi	EA8171	N		
	Y	ALLIANCE	A031701 Bladder, ddGC for MIBC with DDR Tumor Alt	A031701	N		
	Y	ALLIANCE	A031702 GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC)	A031702	N		
	Y	ALLIANCE	A031803 Blad, NMIBC, Gemcitabine + MK-3475	A031803	N		
	Y	NRG	NRGGU011 Pros, Dbl Blinded RT +/- Androgen Dep Tx	NRG-GU011	Y		
	Y	ALLIANCE	A032101 Pros, MHSPC ADT Interruption	A032101	Y		
	Y	NRG	NRGGU012 Renal, Stg IV, Stereo Abl Rad Therapy	NRG-GU012	N		

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close	
		Y	ALLIANCE	A031801 GU, mRCC, Cabozantinib +/- Radium-223	A031801	Y		
	LEUK			A042001 B-Cell ALL, Inotuzanab+chemo v Standard chemo		Y		
				EA9213 T-ALL, dara-hyal for chemo refractory MRD		N		
		Y	ECOG-ACRIN	EA9171 CML, Anti-PD-1 Pembrolizumab + TKIs	EA9171	N		
		Y	ALLIANCE	A041703 ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat	A041703	N		
	LUNG	Y	SWOG	S1933 NSCLC, Stg II-III, RT + Atezo	S1933	N		
		Y	SWOG	S1900G EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu	S1900G	N		
		Y	SWOG	S1900K MET Exon 14: Tepotinib +/- Ramucirumab	S1900K	N		
		Y	SWOG	S1900E KRAS G12C: Sotorasib (AMG 510)	S1900E	N		
		Y	ECOG-ACRIN	EA5162 NSCLS, Stg IV/IIIB, EGFR exon20 insertion, AZD9291	EA5162	N		
	LYMPH	Y	SWOG	S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob	S1608	N		
		Y	SWOG	S2207 LBCL, Transplant Inelig, Targeted Tx + Tafa	S2207	Y		
		Y	SWOG	S2114 NHL, Rel/Ref, CD19 CAR-T +/- Consolidation	S2114	N		
		Y	ALLIANCE	A051902 PTCL, CHO(E)PvCC-486-CHO(E)PvDuvetisib-CHO(E)PA051902		N		
	MELAN			A091903 Melan, Resected Mucosal, Adj Nivo +/- Cabo		Y		
		Y	SWOG	S2000 MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo	S2000	N		
		Y	ECOG-ACRIN	EA6194 Melan, Stage IIIB-D, Pembro +/- CMP-001	EA6194	N		
		Y	ECOG-ACRIN	EA6192 Melan, Adv, Erly Discont of Antibdy Thrpy	EA6192	N		
	MMYEL	Y	ECOG-ACRIN	EAA173 MYEL, SMM, Rd +/- Daratumumab	EAA173	Y		
	MULT	Y	SWOG	S2101 Melan or HNSCC, Adv, Cabo + Nivo	S2101	N		
	OTHER			A071702 BRAIN, Blockade Tx in Recurrent Glioblastoma		N		
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV, Adj RT +/- Cisp	EA3132	N		
		Y	NRG	NRGHN010 HER2+ SGC, T-DM1 vs TH	NRG-HN010	N		
		Y	ALLIANCE	A071701 BRAIN, Met, Geno-guided trial	A071701	N		
		Y	ALLIANCE	A092107 DDLPS. Palbocicli v Palbociclib+Cemiplimab	A092107	N		
		Y	ECOG-ACRIN	EA3191 HN, High Risk HNSCC, Adj +/- Pembro	EA3191	N		
	PREV			EA8184 Pros, Dbl Blind GTC vs Placebo		Y		
		Y	ECOG-ACRIN	EA2185 Panc, Impact of Panc Cyst Surveillance	EA2185	Y		
	PILOT	PREV	Y	SWOG	S1904 Breast, Decision making for chemoprevention	S1904	Y	
		Y	ECOG-ACRIN	EAQ202 Improving AYA PROs in EA Trials	EAQ202	Y		
	II-III	BREAST	Y	NRG	NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA	NRG-BR002	N	Y
		ERLYTX	Y	SWOG	S2012 Small Cell NEC, Stg IV, Combo Chemo +/- Atezo	S2012	N	
		GI	Y	ECOG-ACRIN	EA2197 Gal, Rando Perioperative TX	EA2197	N	
			Y	ECOG-ACRIN	EA2174 Esoph, Peri-Op Nivolumab +/- Ipilimumab	EA2174	N	
			Y	NRG	NRGGI008 Colon, Stg III, Adj Chemo	NRG-GI008	N	
		GU	Y	ECOG-ACRIN	EA8192 Blad, High Grade UTUC, Durv + Chemo	EA8192	N	
		LEUK	Y	ALLIANCE	A041701 AML, Age 60+, Conv Chemo +/- Uproleselan	A041701	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA	
						Study	Temp Close
	LUNG	Y	ALLIANCE	A082002 Lung, Adv, Systemic Tx +/- SBRT	A082002	Y	
	LYMPH	Y	SWOG	S1918 DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP	S1918	Y	
		Y	ALLIANCE	A051701 LYMPH, MYC/BC2 DHL&DEL, R-chemo+/-Venetoclax	A051701	N	Y
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Adv, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGHN005 HN, early stg P16-pos, randomize de-intensifi	NRG-HN005	Y	
		Y	ECOG-ACRIN	EA3161 HNC, HPV+ OPCA, (cisplatin+RT) +/- Nivo	EA3161	N	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN006 HN, Erly Stg, Biopsy vs Dissection	NRG-HN006	Y	
		Y	NRG	NRGHN009 HN, RT + HD Cisp vs RT + LD Cisp for SCCHN	NRG-HN009	Y	
		Y	ALLIANCE	A092104 Uter,Adv, Olaparib+Temozolomide vs Inv Choice	A092104	N	
	SXQOL	Y	ALLIANCE	A221805 Colorectal, Duloxetine for Oxaliplatin CIPN	A221805	Y	
III	BREAST	Y	SWOG	S2206 Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva	S2206	Y	
		Y	SWOG	S2212 Breast, TNBC, Neoadj Chemo + Pembro	S2212	Y	
		Y	CCTG	MA39 BREAST, Node-Pos, Reg RT vs No Reg RT	CCTG MA.39	Y	
		Y	ALLIANCE	A011801 BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib	A011801	Y	
		Y	ALLIANCE	A012103 Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab	A012103	Y	
		Y	NRG	NRGBR009 Breast, EarlyStg, Adjuvant Chemo	NRG-BR009	N	
		Y	NRG	NRGBR007 Breast, Stg I, De-Escalation of Breast RT	NRG-BR007	Y	
	CCD	Y	SWOG	S1703 Met Breast, STM-monitoring v Usual Care	S1703	Y	
		Y	SWOG	S2108CD Genomic Tumor Board vs Usual Practice	S2108CD	Y	
		Y	SWOG	S1912CD CREDIT, Fin Counseling to reduce Fin Hardship	S1912CD	Y	
		Y	ALLIANCE	A191901 Brst, Text/Motivational Intervention ET Adher	A191901	Y	
	ERLYTX	Y	COG	AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult	AGCT1531	Y	
	GI	Y	NRG	NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy	NRG-GI004	Y	
		Y	ALLIANCE	A021806 Pancreas, Perioperative vs Adjuvant Chemo	A021806	Y	
		Y	ALLIANCE	A022102 Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/- Nivo	A022102	N	
		Y	ECOG-ACRIN	EA2176 Anal, Met, Immune Check Pt Inhibition + Chemo	EA2176	N	
	GU	Y	SWOG	S1806 Blad, MIBC, ChemoRT +/- Atezolizumab	S1806	Y	
		Y	SWOG	S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum	S1802	Y	
		Y	SWOG	S1937 Blad, Mets, Eribulin +/- Gem vs SOC	S1937	N	
		Y	SWOG	S1931 RENAL, Stg IV, IO + Nephrectomy. vs IO Only	S1931	N	
		Y	ALLIANCE	A031704 RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo	A031704	Y	
		Y	ECOG-ACRIN	EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT	EA8134	Y	
		Y	ALLIANCE	A032001 Blad, Met, Cabo +/- Avelumab after Chemo	A032001	Y	
		Y	NRG	NRGGU010 Pros, Parallel De-Intens & Intens Trials	NRG-GU010	Y	
		Y	ECOG-ACRIN	EA8191 Pros, Local vs Systemic Thrpy	EA8191	N	
		Y	ECOG-ACRIN	EA8212 Blad, NMIBC, BRIDGE	EA8212	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	NRG	NRGGU008 Pros,Node+, Abiraterone acetate + Apalutamide	NRG-GU008	Y	
		Y	NRG	NRGGU009 Pros, PREDICT-RT	NRG-GU009	Y	
	LEUK	Y	SWOG	S1925 CLL/SLL, Newly Dx HR, Early vs Delayed V+O	S1925	Y	
		Y	ALLIANCE	A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo	A041501	N	
		Y	ECOG-ACRIN	EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab	EA9181	N	
	LUNG	Y	SWOG	S1827 SCLC, MRI Surveillance +/- PCI	S1827	Y	
		Y	SWOG	S1914 NSCLC, High Risk Early Stg, SBRT +/- Atezo	S1914	Y	
		Y	SWOG	S2302 NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC	S2302	N	
		Y	ECOG-ACRIN	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N	
		Y	ECOG-ACRIN	EA5163 NSCLC, Immunotherapy +/- 2nd line therapy	EA5163	N	
		Y	NRG	NRGLU008 Lung NSCL, StgII-III, StereoBodyRad/MedChemo	NRG-LU008	Y	
		Y	ALLIANCE	A081801 ALCHEMIST4, ALK and EGFR negative, Chemo-IO	A081801	Y	
		Y	ECOG-ACRIN	EA5182 NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291	EA5182	N	
	LYMPH	Y	ECOG-ACRIN	EA4151 Lymph, AHCT +/-Ritux, MRD Neg	EA4151	N	
		Y	ALLIANCE	A052101 Lymph, Stg I-IV, Cont v Intermittent Zanub	A052101	Y	
		Y	COG	ANHL1931 PMBCL, Chemo-Immunotherapy +/- Nivo	ANHL1931	N	
		Y	COG	AHOD2131 cHL,StgII,StdTherapyvImmuno-oncologyTherapy	AHOD2131	Y	
	MELAN	Y	ECOG-ACRIN	EA6174 Merkel, Adjuvant Pembrolizumab vs Observation	EA6174	N	
		Y	MASC	S2015 MELAN, Stg I-II, 1cm v 2cm excision margins	S2015	N	
	MMYEL	Y	SWOG	S1803 MM, Maintenance, Len vs Len/Dara	S1803	N	
		Y	SWOG	S2209 MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D	S2209	Y	
		Y	ECOG-ACRIN	EAA181 Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE)	EAA181	Y	
	OTHER	Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N	
		Y	NRG	NRGBN003 Mening, Grd II, Observation vs Irradiation	NRG-BN003	Y	
		Y	COG	AGCT1532 Inter/Poor Met GCTs, Accel v Std BEP Chemo	AGCT1532	Y	Y
		Y	COG	ARST2031 RMS, Stg IV, VINO-AC+VINO-CPO vs VAC+VINO-CPO	ARST2031	N	
		Y	NRG	NRGBN011 Brain, Lomustine + Temo vs Temo	NRG-BN011	Y	
		Y	NRG	NRGBN012 Brain, Pre- vs Post-Op Stereotactic Radiosurg	NRG-BN012	Y	
		Y	NRG	NRGGY019 Ovar, Stg II-IV, Pac/Carb/Let vs. Let Mono	NRG-GY019	N	
	PREV	Y	ECOG-ACRIN	EA1151 Prev, Tomosynthesis Mammographic Screening	EA1151	N	
		Y	NRG	NRGCC005 Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs	NRG-CC005	Y	
	SURV	Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y	Y
		Y	ALLIANCE	A211901 Cancer survivors who smoke, txt cessation	A211901	Y	
	SXQOL	Y	SWOG	S2010 ASPEN: Brst, Stg I-III, ASM vs Pt Ed	S2010	Y	
		Y	SWOG	S2205 ICE COMPRESS: Reduction of CIPN from Taxanes	S2205	Y	
		Y	ALLIANCE	A222004 Mult, Olanza vs Megestrol for Anorexia	A222004	Y	
		Y	NRG	NRGCC010 Endo, Stg I, LN Map for LE Limb Dysfunction	NRG-CC010	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

<u>Phase</u>	<u>Comm.</u>	<u>Int</u> <u>grp</u>	<u>Stat</u> <u>Center</u>	<u>Study</u>	<u>NCIPROTO</u>	<u>CA</u> <u>Cntrl</u>	<u>Temp</u> <u>Close</u>
				NRGBN005			
		Y	CCTG	CCTGHN11	CCTG-HN11		
		Y	ALLIANCE	EAY191A3	EAY191-A3		
111	MMYEL	Y	SWOG	S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT	S2213	Y	

**PHASE III SWOG COORDINATED OPEN STUDIES
SORTED BY STUDY ID**

Protocol Number	Study	Accrual Goal	Open Stat/Date	Months Open	Accrual as of 01Jan02	Current Accrual	Proj. Annual Accr. Rate	EXPCLOSE	Proj. Study Duration (Years)
S1501 S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV)	817	T-09/15/17	77	310	310	20	> 15 Yrs	> 15 Yrs
S1703 S1703	Met Breast, STM-monitoring v Usual Care (CCD)	739	Y-07/16/18	67	320	320	48	Oct-2032	14.3
S1802 S1802	Pros, Stg IV, SST +/- Surg/RT to Primary Tum (GU)	1273	Y-09/17/18	65	767	767	120	Apr-2028	9.6
S1803 S1803	MM, Maintenance, Len vs Len/Dara (MMYEL)	1100	Y-06/27/19	55	1077	1077	72	May-2024	4.9
S1806 S1806	Blad, MIBC, ChemoRT +/- Atezolizumab (GU)	475	Y-04/19/19	58	478	478	106	Feb-2024	4.8
S1827 S1827	SCLC, MRI Surveillance +/- PCI (LUNG)	668	Y-01/10/20	49	202	202	68	Dec-2030	11.0
S1912CD S1912CD	CREDIT, Fin Counseling to reduce Fin Hardship (CCD)	326	Y-07/26/21	30	200	200	198	Sep-2024	3.2
S1914 S1914	NSCLC, High Risk Early Stg, SBRT +/- Atezo (LUNG)	480	Y-03/25/20	46	322	322	158	Jan-2025	4.8
S1918 S1918	DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP (LYMPH)	422	Y-03/19/21	35	88	88	50	Oct-2030	9.6
S1925 S1925	CLL/SLL, Newly Dx HR, Early vs Delayed V+O (LEUK)	247	Y-12/14/20	38	92	92	34	Aug-2028	7.7
S1931 S1931	RENAL, Stg IV, IO + Nephrectomy. vs IO Only (GU)	332	Y-11/16/20	39	87	87	34	Apr-2031	10.4
S1937 S1937	Blad, Mets, Eribulin +/- Gem vs SOC (GU)	465	Y-02/16/21	36	23	23	0	> 15 Yrs	> 15 Yrs
S2010 S2010	ASPEN: Brst, Stg I-III, ASM vs Pt Ed (SXQOL)	540	Y-01/17/23	13	218	218	302	Feb-2025	2.1
S2012 S2012	Small Cell NEC, Stg IV, Combo Chemo +/- Atezo (ERLYTX)	189	Y-12/02/21	26	37	37	28	Jul-2029	7.6
S2108CD S2108CD	Genomic Tumor Board vs Usual Practice (CCD)	1182	Y-08/22/22	18	882	882	700	Jul-2024	1.9
S2205 S2205	ICE COMPRESS: Reduction of CIPN from Taxanes (SXQOL)	777	Y-03/16/23	11	90	90	144	Nov-2028	5.7
S2206 S2206	Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva (BREAST)	960	Y-10/30/23	3	2	2	6.345008	> 15 Yrs	> 15 Yrs
S2209 S2209	MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D (MMYEL)	510	Y-05/30/23	8	15	15	30	> 15 Yrs	> 15 Yrs
S2212 S2212	Breast, TNBC, Neoadj Chemo + Pembro (BREAST)	2400	Y-07/21/23	7	57	57	114	> 15 Yrs	> 15 Yrs
S2302 S2302	NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC (LUNG)	700	Y-03/06/23	11	345	345	500	Oct-2024	1.6

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.